Turning Complex Biology into Actionable Insights
RefinedScience systematically de-risks oncology drug assets by integrating high-fidelity clinical data with single-cell human tissue biology and functional testing to drive actionable insights from target to trial.
The Problem
Most drug discovery systems optimize inside simplified models of biology that fail to reflect the complexity of human biology.
The root cause of oncology program failure is biology, not technology.
Preclinical models built on cell lines don’t reflect the complexity of human tumors. Drugs that work in simplified systems routinely fail when they encounter real biology.
Patient heterogeneity is rarely captured at the resolution that matters. Programs enter Phase II without knowing which patients are most likely to respond — or which cells drive relapse.
As a result, promising therapies are abandoned before the right biology or patient population is understood.
The consequence is predictable: strong scientific hypotheses collapse in clinical trials, and potentially valuable therapies are abandoned before the right patients are identified.
The RefinedScience Platform
What AI alone cannot provide. A platform designed to connect biological discovery with biological reality
Let’s Advance Smarter Drug Development
Whether you are seeking decision-ready insight, structured clinical data collaboration, or joint asset development, RefinedScience partners with teams committed to improving drug development outcomes.